| pubmed-article:9002118 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0010674 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C2709248 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0007559 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0008809 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0040341 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C1579762 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C0009491 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9002118 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:9002118 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9002118 | pubmed:dateCreated | 1997-4-9 | lld:pubmed |
| pubmed-article:9002118 | pubmed:abstractText | Cystic fibrosis patients have chronic bacterial infections of the respiratory tract, most commonly Pseudomonas aeruginosa. Although controversial, administration of antibiotic therapy during acute pulmonary exacerbations is standard practice. Fluoroquinolones are currently not indicated for use in young children because of the observation of arthropathy and damage to growing cartilage in beagle puppies. Because of its activity against P. aeruginosa and excellent oral bioavailability, ciprofloxacin offers a unique therapeutic alternative for this patient population. | lld:pubmed |
| pubmed-article:9002118 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9002118 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9002118 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9002118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9002118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9002118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9002118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9002118 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9002118 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9002118 | pubmed:issn | 0891-3668 | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:StevensJ CJC | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:EcholsR MRM | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:KuhnR JRJ | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:ChurchD ADA | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:PainterB GBG | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:SpohnW AWA | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:KangaJ FJF | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:RubioT TTT | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:HaverstockD... | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:ThurbergB EBE | lld:pubmed |
| pubmed-article:9002118 | pubmed:author | pubmed-author:PerroncelR... | lld:pubmed |
| pubmed-article:9002118 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9002118 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:9002118 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9002118 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9002118 | pubmed:pagination | 97-105; discussion 123-6 | lld:pubmed |
| pubmed-article:9002118 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:meshHeading | pubmed-meshheading:9002118-... | lld:pubmed |
| pubmed-article:9002118 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9002118 | pubmed:articleTitle | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. | lld:pubmed |
| pubmed-article:9002118 | pubmed:affiliation | University of Kentucky Medical Center, Lexington, USA. | lld:pubmed |
| pubmed-article:9002118 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9002118 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9002118 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:9002118 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9002118 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9002118 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9002118 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9002118 | lld:pubmed |
